BIOCERES CROP SOLUTIONS CORP (BIOX) Fundamental Analysis & Valuation

NASDAQ:BIOX • KYG1117K1141

Current stock price

0.5919 USD
-0.05 (-7.25%)
At close:
0.5919 USD
0 (0%)
After Hours:

This BIOX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. BIOX Profitability Analysis

1.1 Basic Checks

  • BIOX had negative earnings in the past year.
  • BIOX had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: BIOX reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: BIOX reported negative operating cash flow in multiple years.
BIOX Yearly Net Income VS EBIT VS OCF VS FCFBIOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

1.2 Ratios

  • BIOX's Return On Assets of -42.75% is on the low side compared to the rest of the industry. BIOX is outperformed by 92.68% of its industry peers.
  • Looking at the Return On Equity, with a value of -313.53%, BIOX is doing worse than 92.68% of the companies in the same industry.
  • BIOX has a Return On Invested Capital of 0.77%. This is in the lower half of the industry: BIOX underperforms 69.51% of its industry peers.
Industry RankSector Rank
ROA -42.75%
ROE -313.53%
ROIC 0.77%
ROA(3y)-1.49%
ROA(5y)-1.52%
ROE(3y)-4.41%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
BIOX Yearly ROA, ROE, ROICBIOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • With a Operating Margin value of 0.95%, BIOX is not doing good in the industry: 68.29% of the companies in the same industry are doing better.
  • The Gross Margin of BIOX (38.78%) is better than 82.93% of its industry peers.
  • In the last couple of years the Gross Margin of BIOX has declined.
Industry RankSector Rank
OM 0.95%
PM (TTM) N/A
GM 38.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
BIOX Yearly Profit, Operating, Gross MarginsBIOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BIOX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIOX is destroying value.
  • Compared to 1 year ago, BIOX has more shares outstanding
  • BIOX has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, BIOX has a worse debt to assets ratio.
BIOX Yearly Shares OutstandingBIOX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
BIOX Yearly Total Debt VS Total AssetsBIOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • The Debt to FCF ratio of BIOX is 3.20, which is a good value as it means it would take BIOX, 3.20 years of fcf income to pay off all of its debts.
  • BIOX's Debt to FCF ratio of 3.20 is amongst the best of the industry. BIOX outperforms 87.80% of its industry peers.
  • BIOX has a Debt/Equity ratio of 0.55. This is a neutral value indicating BIOX is somewhat dependend on debt financing.
  • BIOX has a better Debt to Equity ratio (0.55) than 63.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.2
Altman-Z N/A
ROIC/WACC0.13
WACC5.93%
BIOX Yearly LT Debt VS Equity VS FCFBIOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 0.90 indicates that BIOX may have some problems paying its short term obligations.
  • With a Current ratio value of 0.90, BIOX is not doing good in the industry: 92.68% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.70 indicates that BIOX may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.70, BIOX is not doing good in the industry: 84.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.7
BIOX Yearly Current Assets VS Current LiabilitesBIOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIOX Growth Analysis

3.1 Past

  • The earnings per share for BIOX have decreased strongly by -3272.41% in the last year.
  • The Revenue for BIOX has decreased by -30.08% in the past year. This is quite bad
  • Measured over the past years, BIOX shows a quite strong growth in Revenue. The Revenue has been growing by 14.10% on average per year.
EPS 1Y (TTM)-3272.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-988.89%
Revenue 1Y (TTM)-30.08%
Revenue growth 3Y0.5%
Revenue growth 5Y14.1%
Sales Q2Q%-30.99%

3.2 Future

  • BIOX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.67% yearly.
  • BIOX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.87% yearly.
EPS Next Y79.63%
EPS Next 2Y51.42%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue Next Year-17.52%
Revenue Next 2Y6.62%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BIOX Yearly Revenue VS EstimatesBIOX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BIOX Yearly EPS VS EstimatesBIOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 1

More info and screens

Find the best growth stocksShow best growing peers

6

4. BIOX Valuation Analysis

4.1 Price/Earnings Ratio

  • BIOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • BIOX is valuated cheaply with a Price/Forward Earnings ratio of 2.52.
  • BIOX's Price/Forward Earnings ratio is rather cheap when compared to the industry. BIOX is cheaper than 100.00% of the companies in the same industry.
  • BIOX is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.62, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 2.52
BIOX Price Earnings VS Forward Price EarningsBIOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BIOX is on the same level as its industry peers.
  • 100.00% of the companies in the same industry are more expensive than BIOX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 0.5
EV/EBITDA 12.71
BIOX Per share dataBIOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as BIOX's earnings are expected to grow with 39.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.42%
EPS Next 3Y39.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIOX Dividend Analysis

5.1 Amount

  • No dividends for BIOX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOX Fundamentals: All Metrics, Ratios and Statistics

BIOCERES CROP SOLUTIONS CORP

NASDAQ:BIOX (4/23/2026, 8:00:01 PM)

After market: 0.5919 0 (0%)

0.5919

-0.05 (-7.25%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)03-13
Earnings (Next)05-07
Inst Owners31.55%
Inst Owner Change0%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap37.78M
Revenue(TTM)285.07M
Net Income(TTM)-239.56M
Analysts43.33
Price Target2.04 (244.65%)
Short Float %2.35%
Short Ratio1.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP-0.03%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-137.16%
Min EPS beat(2)-212.04%
Max EPS beat(2)-62.27%
EPS beat(4)1
Avg EPS beat(4)-300.6%
Min EPS beat(4)-1015.03%
Max EPS beat(4)86.93%
EPS beat(8)1
Avg EPS beat(8)-312.5%
EPS beat(12)2
Avg EPS beat(12)-105.66%
EPS beat(16)2
Avg EPS beat(16)-119.1%
Revenue beat(2)0
Avg Revenue beat(2)-20.37%
Min Revenue beat(2)-24.73%
Max Revenue beat(2)-16.01%
Revenue beat(4)0
Avg Revenue beat(4)-20.56%
Min Revenue beat(4)-34.42%
Max Revenue beat(4)-7.07%
Revenue beat(8)0
Avg Revenue beat(8)-18.11%
Revenue beat(12)2
Avg Revenue beat(12)-11.33%
Revenue beat(16)5
Avg Revenue beat(16)-1.92%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)41.18%
EPS NY rev (1m)0%
EPS NY rev (3m)45.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.52
P/S 0.13
P/FCF 0.5
P/OCF 0.46
P/B 0.49
P/tB N/A
EV/EBITDA 12.71
EPS(TTM)-0.92
EYN/A
EPS(NY)0.23
Fwd EY39.64%
FCF(TTM)1.17
FCFY198.33%
OCF(TTM)1.28
OCFY216.74%
SpS4.47
BVpS1.2
TBVpS-0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -42.75%
ROE -313.53%
ROCE 1.17%
ROIC 0.77%
ROICexc 0.81%
ROICexgc 1.86%
OM 0.95%
PM (TTM) N/A
GM 38.78%
FCFM 26.28%
ROA(3y)-1.49%
ROA(5y)-1.52%
ROE(3y)-4.41%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
F-Score4
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.2
Debt/EBITDA 2.04
Cap/Depr 38.63%
Cap/Sales 2.44%
Interest Coverage 0.2
Cash Conversion 395.37%
Profit Quality N/A
Current Ratio 0.9
Quick Ratio 0.7
Altman-Z N/A
F-Score4
WACC5.93%
ROIC/WACC0.13
Cap/Depr(3y)96.4%
Cap/Depr(5y)121.83%
Cap/Sales(3y)4.91%
Cap/Sales(5y)4.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3272.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-988.89%
EPS Next Y79.63%
EPS Next 2Y51.42%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue 1Y (TTM)-30.08%
Revenue growth 3Y0.5%
Revenue growth 5Y14.1%
Sales Q2Q%-30.99%
Revenue Next Year-17.52%
Revenue Next 2Y6.62%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
EBIT growth 1Y-91.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1110.35%
FCF growth 3YN/A
FCF growth 5Y38.53%
OCF growth 1Y176.61%
OCF growth 3YN/A
OCF growth 5Y34.31%

BIOCERES CROP SOLUTIONS CORP / BIOX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIOCERES CROP SOLUTIONS CORP (BIOX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIOX.


Can you provide the valuation status for BIOCERES CROP SOLUTIONS CORP?

ChartMill assigns a valuation rating of 6 / 10 to BIOCERES CROP SOLUTIONS CORP (BIOX). This can be considered as Fairly Valued.


What is the profitability of BIOX stock?

BIOCERES CROP SOLUTIONS CORP (BIOX) has a profitability rating of 2 / 10.


What is the earnings growth outlook for BIOCERES CROP SOLUTIONS CORP?

The Earnings per Share (EPS) of BIOCERES CROP SOLUTIONS CORP (BIOX) is expected to grow by 79.63% in the next year.


How sustainable is the dividend of BIOCERES CROP SOLUTIONS CORP (BIOX) stock?

The dividend rating of BIOCERES CROP SOLUTIONS CORP (BIOX) is 0 / 10 and the dividend payout ratio is -0.03%.